REGEIVED CENTRAL FAX CENTER

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION U.S.S.N. 10/696,770

APR 17 2008

Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

What is claimed:

1. (Currently amended) A method of increasing an immune response to a target in an individual comprising, administering to the individual an effective amount of a composition comprising

one or more immunity linkers, wherein the immunity linkers comprise at least one first binding site and at least one second binding site,

wherein the first binding site comprises a first polypeptide expressed by a <u>first</u> bacteriophage and

wherein the second binding site comprises a second polypeptide expressed by a the first bacteriophage,

wherein the second binding site binds to the target and

wherein the individual has a pre-existing immune response to the first binding site, and

wherein the immune response is selected from a cellular immune response, and a humoral immune response, and an innate immune response.

- 2. (original) The method of Claim 1, wherein the pre-existing immune response is induced by administering to the individual a universal immunogen comprising the first binding site.
- 3. (original) The method of Claim 1, wherein the pre-existing immune response is induced by administering to the individual a universal immunogen that is an immunological equivalent of the first binding site.
- 4. (original) The method of Claim 1, wherein the pre-existing immune response exists in the individual without administration of a universal immunogen.
 - 5. (cancelled)
 - (cancelled)
 - 7. (original) The method of Claim 1, wherein the target is a pathogen.
 - 8. (cancelled)

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION U.S.S.N. 10/696,770

404-572-5135

- 9. (cancelled)
- 10. (Previously presented) The method of Claim 1, wherein the pre-existing immune response is induced by administering to the individual a universal immunogen comprising a second bacteriophage that expresses the first polypeptide.
- 11. (original) The method of Claim 10, wherein the first bacteriophage and/or the second bacteriophage are each contained within one or more bacteria.
 - 12. (cancelled)
- 13. (original) The method of Claim 1, wherein the individual is unable to mount an effective immune response to the target prior to administration of the immunity linker.
- 14. (Currently amended) The method of Claim 1, wherein the composition comprises one or more different immunity linkers wherein the first binding sites differ in
 - a) their specificity for different epitopes of a component of the immune response components, or
 - b) their affinity for the same epitopes of the immune response component.
- 15. (original) The method of Claim 14, wherein the immune response component comprises an antibody.
- 16. (Previously presented) The method of Claim 1, wherein the composition comprises one or more different immunity linkers comprising second binding sites that differ in
 - a) their specificity for different epitopes on the target, or
 - b) their affinity for the same epitope on the target.
 - 17. (cancelled)
- 18. (Currently amended) A method of diverting a pre-existing immune response in an individual from a antigen to a target comprising, administering to the individual an effective amount of a composition comprising

one or more immunity linkers, wherein the linkers comprise at least one first binding site and at least one second binding site,

wherein the second binding site binds to the target and wherein the antigen comprises the first binding site,

wherein the first binding site comprises a first polypeptide expressed by a <u>first</u> bacteriophage and

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION U.S.S.N. 10/696,770

wherein the second binding site comprises a second polypeptide expressed by a the first bacteriophage.

- 19. (New) The method of claim 18 wherein the composition comprises a second bacteriophage that expresses the first polypeptide.
- 20. (New) The method of Claim 19, wherein the first bacteriophage and/or the second bacteriophage are each contained within one or more bacteria.